Targeted second-line therapies for HR+/HER2-mBC include alpelisib in patients with activating mutations in tumor PIK3CA, which significantly improved PFS in patients with PIK3CA mutations who received alpelisib plus fulvestrant compared to placebo plus fulvestrant [17,18]. The gene discussed is PIK3CA; the disease is neoplasm.